Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 10, 13, 47, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Ache Laboratorios Farmaceuticos SA
Actinogen Medical Ltd
Addex Therapeutics Ltd
Aision Biotechnologies Inc
Algernon Pharmaceuticals Inc
Allied Corp
Alto Neuroscience Inc
Alzamend Neuro Inc
Amorsa Therapeutics Inc
Anagin Inc
Ananda Scientific Inc
Apex Labs Ltd
Aptinyx Inc
ARMGO Pharma Inc
Artelo Biosciences Inc
Avicanna Inc
Better Life Pharmaceuticals Inc
Bionomics Ltd
Bionorica SE
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Braxia Scientific Corp
Bright Minds Biosciences Inc
Cannabis Science Inc
Chronos Therapeutics Ltd
Compass Pathways Plc
Corcept Therapeutics Inc
Delix Therapeutics Inc
Eli Lilly and Co
Embera NeuroTherapeutics Inc
EmpathBio
Endosane Pharmaceuticals GmbH
Enveric Biosciences Inc
EpiVario Inc
Evecxia Therapeutics Inc
Exxel Pharma Inc
H. Lundbeck AS
Halucenex Life Sciences Inc
Immodulon Therapeutics Ltd
INVENT Pharmaceuticals Inc
iX Biopharma Ltd
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kdac Therapeutics Inc
Lactocore Inc
Lennham Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Mindstate Design Labs
Mydecine Innovations Group Inc
Nanomerics Ltd
Neuritek Therapeutics Ltd
NeuroNascent Inc
NeuroPharm Inc
Neurovation Labs Inc
NRX Pharmaceuticals Inc
Omeros Corp
One World Cannabis Ltd
Otsuka Pharmaceutical Co Ltd
PharmaTher Holdings Ltd
Praxis Precision Medicines Inc
Protagenic Therapeutics Inc
Psy Therapeutics Inc
PsyBio Therapeutics Corp
Sage Therapeutics Inc
Sanofi
Scientus Pharma Inc
Seelos Therapeutics, Inc.
Synendos Therapeutics AG
Tonix Pharmaceuticals Holding Corp
Virpax Pharmaceuticals Inc
VistaGen Therapeutics Inc
Wake Network Inc